Related Experiment Videos
[Intervention trials for elderly hypertension in Western countries]
Hiromi Rakugi1, Toshio Ogihara
1Department of Geriatric Medicine, Osaka University Graduate School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 14, 2005
Summary
Treatment for elderly hypertension is essential, but benefits for mild cases and the very elderly remain unclear. The ongoing Hypertension in the Very Elderly Trial (HYVET) aims to resolve these questions for older adults.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Clinical Trials
Context:
- Large-scale trials confirm hypertension treatment necessity in Western elderly, including isolated systolic hypertension.
- Uncertainty remains regarding antihypertensive treatment benefits in mild hypertension and in the very elderly population.
- Existing studies lack data on target blood pressure below 140 mmHg systolic.
Purpose:
- To evaluate the benefit of antihypertensive treatment in very elderly patients with hypertension.
- To clarify the efficacy of current first-line antihypertensive drugs in older adults.
- To address unresolved questions in elderly hypertension management through large-scale trials.
Summary:
- The Hypertension in the Very Elderly Trial (HYVET) is investigating the benefits of treating hypertension in individuals over 80.
- Diuretics and calcium channel blockers are established first-line treatments for elderly hypertension.
- Inhibitors of the renin-angiotensin system also show promise in this demographic.
Impact:
- Findings will guide clinical practice for hypertension management in the very elderly.
- This research may establish new treatment guidelines for a vulnerable patient group.
- Results will inform future large-scale clinical trials in geriatric hypertension.